Rubric :   Topical

The era of «targets» in the treatment strategy of resectable NSCLC: from ADAURA to NeoADAURA…
Т. 14, №2 (54)
New opportunities in first-line therapy of unresectable EGFRm NSCLC. Overview of clinical trials FLAURA, FLAURA2, LAURA
Т. 14, №2 (54)
Modern aspects of diagnosis and treatment of kidney cancer
Т. 14, №2 (54)
New therapeutic options in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Т. 14, №1 (53)
Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: а retrospective analysis of Surveillance, Epidemiology and End Results-Medicare data
Т. 14, №1 (53)
Vaccination as a primary prophylaxis against tumors caused by HPV
Authors: Patsko V.V. Efimenko O.V. Lukashenko A.V. Т. 14, №1 (53)
Expanding the role of immuno-oncology treatment in the management of patients with melanoma or triple-negative breast cancer
Т. 13, №4 (52)
New stage in personalized breast cancer therapy: a chance for recovery
Т. 13, №4 (52)
How to improve the diagnosis and treatment of patients with prostate cancer in Ukraine? Results of the 2023 survey
Т. 13, №4 (52)
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study
Т. 13, №4 (52)
Modern approaches to the diagnosis and treatment of lymphoproliferative diseases
Дата: 2023-12-06
Prospects for the use of pembrolizumab in the treatment of previously untreated patients with advanced malignant pleural mesothelioma
Author:Nemish I.L. Т. 13, № 3 (51)
Talazoparib in the treatment of breast cancer. Analysis of the real-world evidence
Т. 13, № 3 (51)
New stage in personalized breast cancer therapy: a chance for recovery
Т. 13, № 3 (51)
Modern tactics of treatment of relapsed/refractory multiple myeloma
Author:Nemish I.L. Т. 13, № 3 (51)

123